Tianhong Shengjie Announces the Closing of ￥100 Million Series B Financing

(VCBeat) Apr. 20, 2021 -- Tianhong Shengjie, the first one-stop comprehensive product platform in the field of interventional therapy for venous disease in China, has completed the Series B financing of nearly 100 million yuan from its existing and new investors. The new investors include Guolian Investment, Lotus Lake Ventures, Purple Bell Startups and Ningbo Kangtuo that join the existing group of SND Ventures Group and Greenriver Investment. Sanjiang Capital acted as the exclusive financial adviser for this round of financing.

Founded in March 2016, Tianhong Shengjie is the first innovative medical device company focusing on product development in the field of interventional therapy for venous disease in China with independent intellectual property rights. In the five years since its founding, Tianhong Shengjie has been focused on the clinical demands, starting from the R&D of products in urgent needs. In terms of treatment technology and product development in venous diseases, Tianhong Shengjie has senior experts of clinical R&D, providing integrated solutions of intravenous therapy as the leading company in the field of product development for vein disease.

Wang Yonggang, chairman of Tianhong Shengjie, said, "The financing will be mainly used to accelerate the clinical application of products under development, such as iliac vein stents, the further development of product pipelines, and the expansion of production and marketing.

At present, Tianhong Shengjia has obtained four NMPA registration certificates. The company is going to prepare for the registration dossier in the next three years of the products including iliac vein stent, vena cava filter, thrombectomy catheter, thrombolytic catheter, high-pressure balloon, thrombus aspiration catheter and others. Among it, 256 patients with iliac vein stents have been enrolled and followed up.

In the track of interventional therapy for venous disease with lower penetration and rapid growth, Tianhong Shengjia aims to be a one-stop integrated product platform for venous disease, focusing on obstructive diseases, arteriovenous thrombosis, reflux disease, the prevention and cure of VTE, lower limb artery disease, maintenance of vascular access in this field.

Guolian Investment, founded in 2006 with registered capital of 200 million yuan, is the industry investment management platform of Guolian group. It focuses on the IoT, environmental protection and new energy, high-end equipment, biological medicine, and other key sectors in Wuxi. The company is engaged in the fund operation management business, concentrating on all kinds of equity investment and M&A. By the end of 2018, Guolian Investment had managed 23 equity investment funds with a total of 39.1 billion yuan, and invested in 167 enterprises with the full investment of 16.7 billion yuan.

Founded in 2001, Lotus Lake Ventures is an investment firm committed to investing in science and technology innovation enterprises, focusing on high-tech enterprises with core competitiveness in the initial stage and growth stage in the fields of information technology, life science and clean technology, etc.